AR and prostate carcinoma: Most tumors are resistant to AR antagonists due to AR signaling continue to function and drive tumor growth and progression.15 There is an urgent need to develop new treatment strategies to treat prostate cancer, especially metastatic castration refractory prostate cancer (mCRPC).